UK innovation increases cervical cancer detection

​New peer reviewed research published by the European Journal of Obstetrics & Gynecology and Reproductive Biology shows that use of ZedScan in diagnostic screening significantly increased the detection of cancer and potential cancer.

The biggest increase was in women referred with low grade changes, often the most challenging to visualise, where ZedScan had over a 50% increase in high grade disease detection.            

Scientists looked at the examinations of 5257 women by 82 colposcopists in 26 clinics in 9 different countries. The full research can be viewed here and also showed that:        

  • HPV vaccination and primary HPV screening have been shown to be effective
  • Women at low risk of high-grade cervical intra-epithelial neoplasia (CIN) are now being referred to colposcopy
  • In general colposcopy performs poorly when there is a low prevalence of high-grade CIN
  • ZedScan increases the detection of high-grade CIN across multiple centres
  • The study confirms the value of a real time adjunctive technology

Results for all 26 centres showed the sensitivity of colposcopy using the CI method was 74.1% but increased to 91.6% with the use of ZedScan (p < 0.0001). Use of ZedScan increased the detection of high-grade CIN by 269 (24%) cases, a 7.5% increase in high grade cytology and 57.9% in low grade referrals.

ZedScan by Zilico is the British developed and manufactured diagnostic technology for cervical cancer. The technology measures cell changes providing immediate and accurate diagnosis of tissue which may be abnormal. Used by many NHS Trusts and hospitals in Finland, the advanced diagnostic tool will help provide better outcomes for women across the globe.

The cervical screening process screens for HPV infection and those with HPV are referred for colposcopy. In addition to traditional colposcopy methods many NHS Trusts have started using ZedScan for improved diagnostic information provided in real-time. At colposcopy clinicians look for CIN. Cervical cancer is a treatable disease if detected at CIN stage.

Sameer Kothari, CEO, Zilico said: “The publication shows how ZedScan helps across different clinical settings in nine countries. Colposcopy has not materially changed for nearly 100 years and this data shows how having this advanced technology at the point of examination during colposcopy helps patients, clinicians and hospitals. Not only is this technology meaningful for the patient’s comfort and reassurance it is quite simply detecting more problems accurately, and in greater detail, allowing people to access the treatment that they need more efficiently. This is important research here in the UK & Europe, and moreover has huge potential for the rest of the world and developing economies where cervical cancer goes readily undetected.”

Latest Issues

AfPP Annual Conference 2024

University of Warwick
2nd - 3rd August 2024

The Operating Theatres North Show 2024

Etihad Stadium, Manchester
12th September 2024

The AfPP Roadshow - London

Cavendish Conference Centre, London
14th September 2024

Infection Prevention 2024

ICC Birmingham
23rd - 25th September 2024

Future Surgery

ExCeL London
1st - 2nd October 2024